Literature DB >> 24474600

Risk prediction models for chemotherapy-induced nausea and vomiting: almost ready for prime time?

George Dranitsaris1, Mark Clemons.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24474600     DOI： 10.1007/s00520-014-2134-2

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  9 in total

1.  Internal validation of predictive models: efficiency of some procedures for logistic regression analysis.

Authors:  E W Steyerberg; F E Harrell; G J Borsboom; M J Eijkemans; Y Vergouwe; J D Habbema
Journal:  J Clin Epidemiol       Date:  2001-08       Impact factor: 6.437

2.  Prognosis and prognostic research: validating a prognostic model.

Authors:  Douglas G Altman; Yvonne Vergouwe; Patrick Royston; Karel G M Moons
Journal:  BMJ       Date:  2009-05-28

3.  Prognosis and prognostic research: Developing a prognostic model.

Authors:  Patrick Royston; Karel G M Moons; Douglas G Altman; Yvonne Vergouwe
Journal:  BMJ       Date:  2009-03-31

4.  Chemotherapy-induced anaemia during adjuvant treatment for breast cancer: development of a prediction model.

Authors:  George Dranitsaris; Mark Clemons; Sunil Verma; Cathy Lau; Mark Vincent
Journal:  Lancet Oncol       Date:  2005-11       Impact factor: 41.316

5.  Prospective validation of a prediction tool for identifying patients at high risk for chemotherapy-induced nausea and vomiting.

Authors:  George Dranitsaris; Nathaniel Bouganim; Carolyn Milano; Lisa Vandermeer; Susan Dent; Paul Wheatley-Price; Jenny Laporte; Karen-Ann Oxborough; Mark Clemons
Journal:  J Support Oncol       Date:  2013-03

6.  Validation of a transfusion prediction model in head and neck cancer surgery.

Authors:  Nadia L Krupp; Gregory Weinstein; Ara Chalian; Jesse A Berlin; Patricia Wolf; Randal S Weber
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2003-12

7.  Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting.

Authors:  N Bouganim; G Dranitsaris; S Hopkins; L Vandermeer; L Godbout; S Dent; P Wheatley-Price; C Milano; M Clemons
Journal:  Curr Oncol       Date:  2012-12       Impact factor: 3.677

8.  Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib.

Authors:  G Dranitsaris; M D Vincent; J Yu; L Huang; F Fang; M E Lacouture
Journal:  Ann Oncol       Date:  2012-01-06       Impact factor: 32.976

9.  Development and preliminary validation of a risk prediction model for chemotherapy-related nausea and vomiting.

Authors:  A Molassiotis; Z Stamataki; E Kontopantelis
Journal:  Support Care Cancer       Date:  2013-05-30       Impact factor: 3.603
  9 in total
  5 in total

Review 1.  Systemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelines.

Authors:  A A Joy; M Ghosh; R Fernandes; M J Clemons
Journal:  Curr Oncol       Date:  2015-03       Impact factor: 3.677

2.  A cost-utility analysis of risk model-guided versus physician's choice antiemetic prophylaxis in patients receiving chemotherapy for early-stage breast cancer: a net benefit regression approach.

Authors:  Kednapa Thavorn; Doug Coyle; Jeffrey S Hoch; Lisa Vandermeer; Sasha Mazzarello; Zhou Wang; George Dranitsaris; Dean Fergusson; Mark Clemons
Journal:  Support Care Cancer       Date:  2017-03-09       Impact factor: 3.603

3.  Defining optimal control of chemotherapy-induced nausea and vomiting-based on patients' experience.

Authors:  Catalina Hernandez Torres; Sasha Mazzarello; Terry Ng; George Dranitsaris; Brian Hutton; Stephanie Smith; Amy Munro; Carmel Jacobs; Mark Clemons
Journal:  Support Care Cancer       Date:  2015-06-25       Impact factor: 3.603

4.  The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting.

Authors:  G Dranitsaris; A Molassiotis; M Clemons; E Roeland; L Schwartzberg; P Dielenseger; K Jordan; A Young; M Aapro
Journal:  Ann Oncol       Date:  2017-06-01       Impact factor: 32.976

5.  A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting.

Authors:  M Clemons; G Dranitsaris; M Sienkiewicz; S Sehdev; T Ng; A Robinson; M Mates; T Hsu; S McGee; O Freedman; V Kumar; D Fergusson; B Hutton; L Vandermeer; J Hilton
Journal:  Breast       Date:  2020-11-10       Impact factor: 4.380
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.